Jan van de Winkel, CEO of Genmab | Foto: /Ritzau Scanpix/Sofie Mathiassen

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Foto: Leo Pharma / PR

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Future uncertain for Orphazyme CEO as firm sold

Although the plan is that the majority of Orphazyme’s 20 remaining employees will now work for the new owner, US-based Kempharm, it is not yet clear whether CEO Anders Vadsholt will join them, he tells MedWatch.

Orphazyme sells entire business to US biotech company

Embattled biotech company Orphazyme has found a buyer in the form of a US-based biotech firm. If and when the deal is completed, the Danish company will close, and the majority of the remaining 20 employees will be transferred to the new owner.

Orphazyme didn't know buyer before negotiations began

US-based Kempharm, which is set to purchase embattled Orphazyme, was until negotiations began relatively unknown to the Danish firm, according to CEO Anders Vadsholt, who still calls this the best solution considering the firm’s current situation.


FDA approves Eli Lilly diabetes drug

Tirzepatide, a treatment for type 2 diabetes developed by Eli Lilly, has been approved by the FDA, setting the stage for a direct competition with Novo Nordisk’s Ozempic.

Genmab CEO on royalties defeat: "I'm sad and disappointed"

In April, Genmab suffered a defeat in an arbitration case concerning drug Darzalex. Though he had hoped for a different outcome, CEO Jan van de Winkel says it was a ”complex” decision not to contest the ruling, and that a conclusion was sorely needed.

Latest news

See all jobs